Abstract
The severity of COVID-19, lack of specific treatment, and controversies on the vaccine's efficacy demand the development of new drugs against SARS-CoV-2. Fungi produce various metabolites with diverse molecular structures that have emerged as promising antiviral drug candidates. Therefore, the present study aimed to investigate medicinal fungi derived secondary metabolites as potential inhibitors of 3 different targets associated with viral entry (human TMPRSS2) and replication (main and papain-like protease) through molecular docking and dynamic simulation studies. Based on our findings, we identified Phelligridin E, Lepiotaprocerine G, and Inoscavin A as the potential blockers of SARS-CoV-2 main protease, papain-like protease, and human TMPRSS2, respectively. These compounds strongly interacted with their corresponding target, passed Lipinski Rule's and had acceptable ADMET properties. Drug-protein complexes showed good stability during MD simulation. Estimation of binding free energy using the MM-GBSA method validated the inhibitor potential of identified compounds. Taken together, we believe that further in vitro and in vivo investigations on our proposed molecules may contribute to expanding the therapeutic arsenal in our fight against COVID-19.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
